

Supplementary Materials

Table S1 – List of Skewed Parameters

Skewed parameters were log-transformed before Cox regression. Shapiro-Wilk was used.

Total Cohort	Cohort 1	Cohort 2
PD-L1	PD-L1	PD-L1
PD-L2		
Macrophages M1/M0	Macrophages M1/M0	Macrophages M1/M0
Macrophages M2/M0	Macrophages M2/M0	Macrophages M2/M0
Dendritic cells activated/resting	Dendritic cells activated/resting	
NK cells activated/resting	NK cells activated/resting	NK cells activated/resting

Table S2 – Multivariate Cox Regression of PD-L2 Expression with all Interferon Type 1 Genes

	<i>HR [95%CI]</i>	<i>p-value</i>
<i>PD-L2</i>	0.98 [0.94 - 1.01]	0.230
<i>IFNA1</i>	1.02 [0.94 - 1.11]	0.567
<i>PD-L2</i>	0.97 [0.93 - 1.01]	0.184
<i>IFNA2</i>	0.91 [0.76 - 1.10]	0.339
<i>PD-L2</i>	0.99 [0.95 - 1.02]	0.417
<i>IFNA4</i>	1.04 [0.95 - 1.15]	0.387
<i>PD-L2</i>	0.98 [0.95 - 1.01]	0.253
<i>IFNA5</i>	0.91 [0.80 - 1.03]	0.126
<i>PD-L2</i>	0.97 [0.93 - 1.00]	0.036
<i>IFNA6</i>	0.92 [0.85 - 1.00]	0.039
<i>PD-L2</i>	0.98 [0.94 - 1.02]	0.319
<i>IFNA7</i>	1.01 [0.90 - 1.13]	0.883
<i>PD-L2</i>	0.98 [0.94 - 1.02]	0.229
<i>IFNA8</i>	0.93 [0.80 - 1.07]	0.280
<i>PD-L2</i>	0.98 [0.95 - 1.02]	0.334
<i>IFNA10</i>	1.03 [0.92 - 1.14]	0.648
<i>PD-L2</i>	0.99 [0.95 - 1.02]	0.363
<i>IFNA13</i>	0.90 [0.78 - 1.03]	0.128
<i>PD-L2</i>	0.98 [0.94 - 1.01]	0.221
<i>IFNA14</i>	0.95 [0.86 - 1.04]	0.273
<i>PD-L2</i>	0.98 [0.95 - 1.01]	0.244
<i>IFNA16</i>	1.00 [0.94 - 1.06]	0.986
<i>PD-L2</i>	0.98 [0.95 - 1.02]	0.381
<i>IFNA17</i>	1.04 [0.94 - 1.17]	0.445
<i>PD-L2</i>	0.97 [0.94 - 1.01]	0.149
<i>IFNA21</i>	0.93 [0.79 - 1.09]	0.353
<i>PD-L2</i>	0.98 [0.95 - 1.01]	0.225
<i>IFNB1</i>	0.97 [0.87 - 1.09]	0.616
<i>PD-L2</i>	0.96 [0.91 - 1.01]	0.123
<i>IFNE</i>	0.83 [0.68 - 1.02]	0.072
<i>PD-L2</i>	0.98 [0.94 - 1.02]	0.233
<i>IFNW1</i>	0.97 [0.80 - 1.18]	0.765
<i>PD-L2</i>	0.97 [0.93 - 1.01]	0.162
<i>IFNK</i>	1.01 [0.98 - 1.04]	0.419

Figure S1 – Simplified Tumor Microenvironment

DNA damage induces the activation of two opposing pathways: one immunostimulatory pathway leads to increased release of interferon alpha via the activation of NF- κ B and type 1 interferon, among others, and thus to activation of the antigen-presenting cells. The second pathway contributes to increased immune evasion via increased reading of *PD-L1/2*. Interferon gamma leads to increased immune evasion in the tumor cell itself. On the other hand, it also leads to an activation of the antigen-presenting cells by stimulating the differentiation of macrophages. Figure based on Shi et al. [5] Created with Biorender.

